Literature DB >> 4688317

Products of activated lymphocytes. I. The use of radiolabeling techniques in the characterization and partial purification of the migration inhibition factor of the guinea pig.

C Sorg, B R Bloom.   

Abstract

General methods were developed and applied to the biosynthesis and purification of products of activated lymphocytes available in minute quantities. The activity studied here was the migration inhibitory factor (MIF) produced by purified protein derivative (PPD)- or concanavalin A (Con A)-stimulated lymphocytes obtained from one guinea pig or less. The methods selected yielded results in terms of two chemical parameters characteristic of the molecules involved, namely K(d) on Sephadex G-75 and isoionic point, pI, on isoelectric focusing. When supernatants were fractionated on G-75 columns, there were several areas even in control supernatants which produced migration inhibition relative to medium controls. However, in PPD- and Con A-stimulated supernatants, at least one peak of MIF activity was found solely in the stimulated cultures, with a K(d) of 0.15. A double-labeling technique was used to characterize the proteins of this peak. Control, unstimulated cultures were labeled with [(14)C]leucine and stimulated cultures were labeled with [(3)H]leucine. After mixing the supernatants and G-75 filtration, a major "ratiolabeled" broad peak. i.e. one with increased (3)H/(14)C ratio, was found. When a narrow portion of this peak about K(d) 0.15, containing most of the MIF activity, was subjected to analytical isoelectric focusing, all of the label was associated with proteins of lower net charge than albumin. A unique ratiolabeled peak was found in PPD- and Con A-stimulated fractions with a pI of approx. 5.3. A micropreparative isoelectric focusing technique was developed and yielded MIF activity in the same region as the major ratiolabeled peak. Further study will be required to ascertain whether the ratiolabeled protein is MIF. By following the K(d), pI, and (3)H/(14)C labeling ratio, at least 14 products of activated lymphocytes, synthesized either de novo or in increased amounts, could be distinguished.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4688317      PMCID: PMC2139369          DOI: 10.1084/jem.137.1.148

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  18 in total

1.  Studies on the migration inhibitory factor associated with delayed-type hypersensitivity: cytodynamics and specificity.

Authors:  B Bennett; B R Bloom
Journal:  Transplantation       Date:  1967-07       Impact factor: 4.939

2.  Interaction between 'sensitized lymphocytes' and antigen in vitro. I. The release of a skin reactive factor.

Authors:  E Pick; J Krejci; K Cech; J L Turk
Journal:  Immunology       Date:  1969-11       Impact factor: 7.397

3.  Formation of covalent circles of lambda DNA by E. coli extracts.

Authors:  M Gellert
Journal:  Proc Natl Acad Sci U S A       Date:  1967-01       Impact factor: 11.205

4.  Studies on production of biologically active substances which inhibit cell migration in supernatants and extracts of hypersensitive lymphoid cells incubated with specific antigen in vitro.

Authors:  J Svejcar; J Pekárek; J Johanovský
Journal:  Immunology       Date:  1968-07       Impact factor: 7.397

5.  The immunological specificity of a macrophage inhibition factor.

Authors:  H E Amos; P J Lachmann
Journal:  Immunology       Date:  1970-02       Impact factor: 7.397

6.  Two fractions with macrophage migration inhibitory activity from sensitized lymphocyte cultures.

Authors:  T Yoshida; R A Reisfeld
Journal:  Nature       Date:  1970-05-30       Impact factor: 49.962

7.  Studies on the intracellular synthesis of reovirus-specified proteins.

Authors:  H J Zweerink; W K Joklik
Journal:  Virology       Date:  1970-07       Impact factor: 3.616

8.  Reactions in vivo and in vitro produced by a soluble substance associated with delayed-type hypersensitivity.

Authors:  B Bennett; B R Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  1968-03       Impact factor: 11.205

9.  Relation of the migration inhibitory factor (MIF) to delayed-type hypersensitivity reactions.

Authors:  B R Bloom; B Bennett
Journal:  Ann N Y Acad Sci       Date:  1970-02-13       Impact factor: 5.691

10.  Suppression of delayed hypersensitivity in vitro by inhibition of protein synthesis.

Authors:  J R David
Journal:  J Exp Med       Date:  1965-12-01       Impact factor: 14.307

View more
  8 in total

Review 1.  The biochemistry and in vitro activity of soluble factors of activated lymphocytes.

Authors:  C Sorg
Journal:  Mol Cell Biochem       Date:  1979-12-14       Impact factor: 3.396

2.  Macrophage aggregation factor: some properties.

Authors:  P Badenoch-Jones
Journal:  Immunology       Date:  1982-07       Impact factor: 7.397

3.  Purification of guinea pig pH 3 migration inhibitory factor.

Authors:  H G Remold; P L McCarthy; A D Mednis
Journal:  Proc Natl Acad Sci U S A       Date:  1981-07       Impact factor: 11.205

4.  Studies on guinea-pig macrophage migration inhibitory factor (MIF). I. Glycoprotein nature and net charge.

Authors:  P Kotkes; E Pick
Journal:  Clin Exp Immunol       Date:  1979-09       Impact factor: 4.330

5.  Chemical properties of antigen-dependent migration inhibition factor in mice.

Authors:  J Krejci; J Pekarek; L Rozprimova; J Svejcar; J Johanovsky
Journal:  Immunology       Date:  1976-08       Impact factor: 7.397

6.  Purification of antigen-dependent macrophage migration inhibition factor (MIF) from lymph draining a tuberculin reaction.

Authors:  D M Scott; I McConnell; P Agomo; P J Lachmann
Journal:  Immunology       Date:  1978-04       Impact factor: 7.397

7.  Partial characterization of murine and monkey helper factor to a streptococcal antigen.

Authors:  E D Zanders; J R Lamb; S Kontiainen; T Lehner
Journal:  Immunology       Date:  1980-11       Impact factor: 7.397

8.  Human migration inhibitory factor: purification and immunochemical characterization.

Authors:  L H Block; H Jaksche; S Bamberger; G Ruhenstroth-Bauer
Journal:  J Exp Med       Date:  1978-02-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.